Unum Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch UMRX and buy or sell other stocks, ETFs, and their options commission-free!About UMRX
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
CEOAndrew R. Robbins, MBA
CEOAndrew R. Robbins, MBA
Employees205
Employees205
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2014
Founded2014
Employees205
Employees205
UMRX Key Statistics
Market cap1.31B
Market cap1.31B
Price-Earnings ratio-16.89
Price-Earnings ratio-16.89
Dividend yield—
Dividend yield—
Average volume2.55M
Average volume2.55M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$43.73
52 Week high$43.73
52 Week low$3.72
52 Week low$3.72
Stock Snapshot
Unum Therapeutics(UMRX) stock is priced at $9.40, giving the company a market capitalization of 1.31B. It carries a P/E multiple of -16.89.
During the trading day, Unum Therapeutics(UMRX) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading activity shows a volume of 0, compared to an average daily volume of 2.55M.
The stock's 52-week range extends from a low of $3.72 to a high of $43.73.
The stock's 52-week range extends from a low of $3.72 to a high of $43.73.
People also own
Based on the portfolios of people who own UMRX. This list is generated using Robinhood data, and it’s not a recommendation.